Dr Jonathan Snicker
Executive Chair and Chief Strategy Officer
20+ years’ experience in variety of Board and Executive roles spanning, business development, philanthropy, university academia, strategic, political, comms and funding advisory.
CEO & Founder
Attomarker is Prof Shaw’s second spinout company, the first having been sold for $8M. He will move to Chief Scientist when the next round is closed
Sakura Holloway
NED, BIF Opportunities LP
Sakura represents Future Planet Capital as Portfolio Manager for their BIF Opportunities Fund, a specialist Life Sciences and AgTech venture capital fund investing in UK university spinouts at Series A/B stage
NED
Experienced Biotech entrepreneur as Chair and Director for many companies leading to trade sales
Strategic Adviser and CCO,
EU Markets
Yves co-led Attomarker’s GBP1.5m Future Fund 2020 funding round. He is a former investment banker (Goldman Sachs, Credit Suisse) and early-stage investor
Chief Strategy Officer
20+ years experience in variety of roles spanning university academia, business development, philanthropy, strategic, political, comms and funding advisory
Global Marketing Director
20+ years’ experience in international strategic & operational healthcare marketing and business development. Director of Integra Healthcare Ltd
CFO
Chartered Accountant from KPMG, with 20 years’ experience as a commercial CFO, gained across a variety of rapid-scale international businesses in diverse sectors
Commercial Director
Twenty-five years of international commercial business experience dedicated to the private and public healthcare markets, focused on market penetration of new innovative digital technologies.
Director of International Development and CEO, Attomarker Asia
Chandru is an investor and former orthopaedic surgeon with deep connections in India and Singapore, with a mission to nurture sustainable technology platforms at ‘India Scale, India Price’.
